Metastatic CRPC: Contemporary Therapeutic Options and Optimal Sequencing
Canadian Oncology Today · 14.04.2026 · 12-17
DOI: 10.58931/cot.2026.3145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Oncology Today, online erschienen am 14.04.2026. Verfasst von Zineb Hamilou. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Prostate cancer (PC) is the most common malignancy among men worldwide. In Canada, an estimated 27,900 new diagnoses were projected in 2024, accounting for approximately 22% of all new cancer cases, with nearly 5,000 related deaths, making PC the fifth leading cause of cancer mortality. Approximately 8% of patients present with metastatic disease at diagnosis. Moreover, rates of de novo metastatic PC have increased in recent years, likely reflecting both the widespread adoption of advanced imaging modalities and reduced systematic screening practices. Initial treatment for recurrent or de novo metastatic castration-sensitive prostate cancer (mCSPC) typically consists of androgen-deprivation therapy (ADT) combined with an androgen receptor pathway inhibitor (ARPI). In patients with high-volume disease, which is defined as ≥4 bone metastases (including ≥1 outside the vertebral column) or the presence of visceral metastases, triplet therapy with ADT, an ARPI, and docetaxel chemotherapy may be employed. In contrast, biochemical recurrence without radiographic metastases is generally managed with ADT alone, with treatment intensification using enzalutamide for patients with a prostate-specific antigen (PSA) doubling time between 3 and 9 months, as supported by the EMBARK trial.
Zitieren
APA
Hamilou, Z. (2026). Metastatic CRPC: Contemporary Therapeutic Options and Optimal Sequencing. Canadian Oncology Today, 12-17. https://doi.org/10.58931/cot.2026.3145
Vancouver
Hamilou Z. Metastatic CRPC: Contemporary Therapeutic Options and Optimal Sequencing. Canadian Oncology Today. 2026:12-17. doi:10.58931/cot.2026.3145
BibTeX
@article{Hamilou2026,
author = {Hamilou, Zineb},
title = {Metastatic CRPC: Contemporary Therapeutic Options and Optimal Sequencing},
journal = {Canadian Oncology Today},
year = {2026},
pages = {12--17},
doi = {10.58931/cot.2026.3145}
}
EUVIMED